Initially approved to improve glycaemic control and reduce cardiovascular death in adults with type 2 diabetes (T2D), the SGLT-2* inhibitor empagliflozin reduced hospitalization for heart failure (HFH) or cardiovascular death and delayed renal function decline when added to recommended therapy in patients with heart failure and reduced ejection fraction (HFrEF) in the EMPEROR-Reduced** trial. The EMPEROR-Preserved** trial has now shown that the benefits of empagliflozin extend to patients with heart failure and preserved ejection fraction (HFpEF).
HFpEF represents a significant unmet need in CV medicine due to
its prevalence, poor prognosis, and the absence of clinically proven
therapeutic options. The EMPEROR-Preserved trial demonstrated the continuous
clinical benefits in cardiorenal outcomes of empagliflozin in adults with
HFpEF, which were consistent with the observations in adults with HFmrEF/
HFpEF in the EMPEROR-reduced trial. The combined results of the EMPEROR
trials establish empagliflozin’s efficacy in heart failure regardless of
ejection fraction – and if approved, empagliflozin would become the first and
only clinically proven therapy to improve outcomes for the full spectrum of
the disease. Therefore, empagliflozin offers a new hope for people living
with heart failure.
Heart failure with preserved
ejection fraction (HFpEF) represents a significant unmet medical need. The
EMPEROR-Preserved trial aimed to assess the impact of empagliflozin on
cardiovascular outcomes in patients with HFpEF. On 27 August 2021, during the
hotline session of the 2021 ESC Virtual Congress, the main results of the
EMPEROR-Preserved trial were presented by Professor Stefan Anker, principal
investigator of the study, and heart failure specialist at Charité Berlin,
Various studies have
shown the beneficial effects of the FreeStyle Libre™ flash glucose monitoring
system for the continuous monitoring of glucose levels in type 1 and type 2
diabetes (T1D and T2D) patients. While clinical trials have demonstrated a
reduced time in hypoglycaemia, fewer hypoglycaemic events per day, and
significant reduction in glycated haemoglobin (HbA1c), real-world data have
shown improved glycaemic control in these patients.
The FreeStyle Libre™ flash glucose
monitoring system includes a sensor which automatically measures and
continuously stores up to 8 hours of glucose readings, allowing patients to
monitor their glucose levels without the need for painful finger pricks.
Physicians play an important role in reviewing and analysing glucose data
that is available through LibreView to support patient management.
Technological advancements have improved glucose
monitoring and diabetes care, as well as empowered patients in self-care. The
introduction of continuous glucose monitoring systems (CGM), such as the
Abbott FreeStyle LibreTM, offers patients an alternative and
additional advantages to self-monitoring of blood glucose (SMBG).
In a webinar held on 27 March 2021, paediatric
endocrinology nurses Karen Blair,
Kate Davies, and Siti Zarina Yaakop shared
insights and clinical experience based
on their frontline roles in caring for patients
with central precocious puberty (CPP)
and supporting their family members.
Chronic coronary syndrome (CCS) remains a leading cause of death and disability worldwide. The dual goals of CCS management is to prevent future cardiac events, such as myocardial infarction and death, and to reduce ischaemia and relieve angina symptoms, says Prof Peter Yan, consultant cardiologist and medical director, Peter Yan Cardiology Clinic, Gleneagles Medical Centre, Singapore, during a Servier-sponsored virtual symposium.